SEC Form 4								
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COM							
	Washington, D.C. 20549	Washington, D.C. 20549						
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	STATEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	OMB Number: 3235 Estimated average burden hours per response:						
	or Section 30(h) of the Investment Company Act of 1940	-						
1. Name and Address of Reporting Person Burke Steven Keith	2. Issuer Name <b>and</b> Ticker or Trading Symbol Akebia Therapeutics, Inc. [ AKBA ]	5. Relationship of R (Check all applicable) Director	eporting Person(s) to Issuer e) 10% Owner					

3. Date of Earliest Transaction (Month/Day/Year)

01/31/2024

C/O AKEBIA THERAPEUTICS, INC													
245 FIRST STREET			4. If Ar	mendment, Date of	Original	Filed	(Month/Day/Ye	6. Indiv Line)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(0)									X	Form filed by One	e Reporting Pers	on	
(Street) CAMBRIDGE	MA	02142								Form filed by Mor Person	e than One Rep	orting	
(City)	(State)	Rule	Rule 10b5-1(c) Transaction Indication										
				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satis the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									
		Table I - No	n-Derivative S	Securities Acq	uired,	, Dis	posed of, o	r Bene	ficially	Owned			
Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Disp Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)		
Common Stock			01/31/2024		A		202,200 <sup>(1)</sup>	Α	\$0.00	735,687 <sup>(2)</sup>	D		
Common Stock 02/01/					S		24,311 <sup>(3)</sup>	D	\$1.68	711,376	D		

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Derivative		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (Right to buy)	\$1.68	01/31/2024		A		303,300		(4)	01/31/2034	Common Stock	303,300	\$0.00	303,300	D	

## Explanation of Responses:

1. The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

2. Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.

3. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31,2023.

4. The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

Remarks:

(Last)

(First)

/s/ Carolyn Rucci, attorney-infact for Steven K. Burke

\*\* Signature of Reporting Person Date

02/02/2024

3235-0287

Other (specify

below)

Officer (give title below)

SVP, Chief Medical Officer

Х

0.5

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Middle)

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.